Parkinson's Diseases - Search News

Dennis Haskins, Mr. Belding in 'Saved by Bell,' dies

‘Saved by the Bell’ actor Dennis Haskins secretly battled Parkinson’s disease in final years, isolated himself from friends

Dennis Haskins reportedly spent his final years battling Parkinson's disease.

· 22h · on MSN

“Saved by the Bell” star Dennis Haskins battled Parkinson’s disease before death at 75

· 1d

Dennis Haskins, 'Saved by the Bell' actor dies. What we know

· 21h

Tiffani Thiessen pays tribute to“ Saved by the Bell” costar Dennis Haskins after his death at 75

Haskins died in Burbank, Calif on Sept. 27 following a private battle with Parkinson's disease.

· 1d

Dennis Haskins, Principal Belding on ‘Saved by the Bell,’ Dies at 75

· 22h

R.I.P. Dennis Haskins, Saved By The Bell's Principal Belding

· 22h

Dennis Haskins, the actor behind Mr. Belding on ‘90s hit ‘Saved by the Bell’ passes away at 75

Mr. Belding may have been the role that made him famous, but Haskins also acted in several other movies and television shows.

· 1d

Dennis Haskins, 'Saved By the Bell' Star, Cut Off Hometown Friends Before His Death

· 1d

‘Saved by the Bell’ actor Dennis Haskins, who played Mr. Belding, dies at 75, reports say

Medscape

FDA Approves First-In-Class Med for Parkinson's Disease

Today's FDA approval of tavapadon makes it the first selective D1/D5 receptor agonist for the treatment of adults with Parkinson's disease.

MedPage Today on MSN

Parkinson's disease gets new treatment approved

FDA gives go-ahead to D1/D5 dopamine agonist tavapadon

MPR

Novel D1/D5 Agonist Juvmo Approved for Parkinson Disease

Juvmo (tavapadon) offers a novel, selective D1/D5 dopamine receptor partial agonist mechanism for early monotherapy and adjunctive treatment in Parkinson disease.

Ask Mayo Clinic: Learn the key difference between essential tremor and Parkinson's disease

Some people live with essential tremor for years and organically find ways to adapt. Others may begin avoiding activities.

U.S. FDA Approves AbbVie's JUVMO™ (tavapadon) for Parkinson's Disease

AbbVie (NYSE: ABBV) today announced that the U.S. Food and Drug Administration (FDA) has approved JUVMO™ (tavapadon) tablets as the first and only selective D1/D5 receptor agonist for the treatment of adults with Parkinson's disease,

1don MSN

FDA approves Juvmo, a first-of-its-kind medication for Parkinson’s disease

The Food and Drug Administration (FDA) recently approved a first-of-its-kind medication for treating Parkinson’s disease. Patients take JUVMO daily, a prescription medication that mimics the effects of dopamine,

VICE

Your Belly Button Could Hold a Surprising Clue to Parkinson’s Disease

A small study found disease-related odor compounds may show up in skin samples, including from the navel, but much larger trials are needed.

Forbes

‘One Of The Most Complex Diseases In Medicine’ — What We Still Don’t Know About Parkinson’s Disease

Forbes contributors publish independent expert analyses and insights. Daryl Austin is a Utah-based reporter who covers health and wellness. April is Parkinson’s Awareness Month, and even though we know more about the disease than ever before, about ...

European Medical Journal

AbbVie wins FDA nod for Parkinson’s disease drug

AbbVie’s JUVMO (tavapadon) is the first and only selective D1/D5 receptor agonist approved for adults with Parkinson’s disease.

16h

Gain Therapeutics Announces Poster Presentation at International Congress of Parkinson’s Disease and Movement Disorders

BETHESDA, Md., Sept. 29, 2026 (GLOBE NEWSWIRE) -- (Nasdaq: GANX) (“Gain”, or the “Company”), a clinical-stage biotechnology company leading the discovery and development of the next generation of allosteric small molecule therapies,